A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
US: FDA approval not reviewed here
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 2 · Enrolling participants
Planned enrollment: 160 participants
Study ages: 18 Years to 75 Years
Recruiting sites listed in: United States
No results-posting date in this record
Read trial record and resultsChecked Nov 16, 2026